Immunologic responses to vaccinia vaccines administered by different parenteral routes

Journal of Infectious Diseases

Volumn 175, Issue 4, 1997, Pages 756-763

  McClain, David J ^a   Harrison, Shannon ^b   Yeager, Curtis L ^c   Cruz, John ^b   Ennis, Francis A ^b   Gibbs, Paul ^b   Wright, Michael S ^d   Summers, Peter L ^b   Arthur, James D ^b   Graham, Jess A ^e  

^a UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^b Madigan Army Medical Center ^*

^c MADIGAN ARMY MEDICAL CENTER   (United States)

^d ABBOTT DIAGNOSTICS   (United States)

^e BROOKE ARMY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; VACCINIA VACCINE;

ANTIBODY DETECTION; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG POTENCY; DRUG SCREENING; FEMALE; HUMAN; INTRADERMAL DRUG ADMINISTRATION; INTRAMUSCULAR DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCAR FORMATION; VACCINIA; VOLUNTEER;

EID: 16944365593     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/513968     Document Type: Article

References (26)

1. Piccini A, Paoletti E. Vaccinia: virus, vector, vaccine. Adv Vir Res 1988; 34:43-64.
2. Moss B. Vaccinia virus: a tool for research and development. Science 1991;252:1662-7.
3. Tartaglia J, Pincus S, Paoletti E. Poxvirus-based vectors as vaccine candidates. Crit Rev Immunol 1990;10:13-30.
4. Rooney JF, Wohlenberg C, Cremer KJ, Moss B, Notkins AL. Immunization with a vaccinia virus recombinant expressing herpes simplex virus type 1 glycoprotein D: long-term protection and effect of revaccination. J Virol 1988;62:1530-4.
5. Kundig TM, Kalberer CP, Hengartner H, Zinkernagel RM. Vaccination with two different vaccinia recombinant viruses: long-term inhibition of secondary vaccination. Vaccine 1993;11:1154-8.
6. Etlinger UM, Altenburger W. Overcoming of inhibition of antibody response's to a malaria recombinant vaccinia virus caused by prior exposure to wild type virus. Vaccine 1991;9:470-2.
7. Centers for Disease Control and Prevention. Vaccinia (smallpox) vaccine. Recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR Morb Mortal Wkly Rep 1991;40:1-10 (erratum: MMWR Morb Mortal Wkly Rep 1992;41:31).
8. Baxby D. Vaccinia Virus. In: Quinnan GV, ed. Vaccinia viruses as vectors for vaccine antigens. New York: Elsevier, 1985:3-8.
9. Henderson DA, Arita I. Utilization of vaccine in the global eradication of smallpox. In: Quinnan GV, ed. Vaccinia viruses as vectors for vaccine antigens. New York: Elsevier, 1985:61-7.
10. Fenner F, Henderson DA, Arita I, Jezek Z, Ladnyi ID. Smallpox and its eradication. Geneva: World Health Organization, 1988:289-94.
11. Lane JM, Ruben FL, Neff JM, Millar JD. Complications of smallpox vaccination, 1968. N Engl J Med 1969;281:1201-8.
12. Chu YK, Rossi C, LeDuc JW, Lee HW, Schmaljohn CS, Dalrymple JM. Serological relationships among viruses in the Hantavirus genus, family Bunyaviridae. Virology 1994;198:196-204.
13. Earley E, Peralta PH, Johnson KM. A plaque neutralization method for arboviruses. Proc Soc Exp Biol Med 1967;125:741-7.
14. Demkowicz WE, Ennis FA. Vaccinia virus-specific CD8*cytotoxic T lymphocytes in humans. J Virol 1993;67:1538-44.
15. Demkowicz W, Littaua R, Wang J, Ennis F. Human cytotoxic T-cell memory: long-lived responses to vaccinia virus. J Virol 1996;70: 627-31.
16. Reed LJ, Muench H. A simple method for estimating fifty percent endpoints. Am J Hyg 1934;27:493-7.
17. Stoline MR. The status of multiple comparisons: simultaneous estimation of all pairwise comparisons in one-way ANOVA designs. Am Stat 1981; 35:134-41.
18. Hekker AC. Tissue culture smallpox vaccine. In: Quinnan GV, ed. Vaccinia viruses as vectors for vaccine antigens. New York: Elsevier, 1985: 113-6.
19. McIntosh K, Cherry JD, Benenson AS, et al. Standard percutaneous revaccination of children who received primary subcutaneous vaccination. J Infect Dis 1977;135:155-66.
20. Cherry JD, Rolfe UT, Dudley JP, Garakian AJ, Murphy M. Clinical and immunological study of percutaneous revaccination in children who originally received smallpox vaccine subcutaneously. J Clin Microbiol 1978;7:158-64.
21. Connor JD, McIntosh K, Cherry JD, et al. Clinical and serologic study of four smallpox vaccines comparing variations of dose and route of administration. Primary subcutaneous vaccination. J Infect Dis 1977; 135:167-75.
22. Rivers TM, Ward SM. Jennerian prophylaxis by means of intradermal injections of culture vaccine virus. J Exp Med 1935;62:549-60.
23. Israel ZR, Edmonson PF, Maul DH, et al. Incomplete protection, but suppression of virus burden, elicited by subunit simian immunodeficiency virus vaccines. J Virol 1994;68:1843-53.
24. Graham S, Green CP, Mason PD, Borysiewicz LK. Human cytotoxic T cell responses to vaccinia virus vaccination. J Gen Virol 1991;72: 1183-6.
25. Tartaglia J, Perkus ME, Taylor J, et al. NYVAC: a highly attenuated strain of vaccinia virus. Virology 1992;188:217-32.
26. Fleury B, Janvier G, Pialoux G, et al. Memory cytotoxic T lymphocyte responses in human immunodeficiency virus type 1 (HIV-1)-negative volunteers immunized with a recombinant gp160 canarypox expressing gp160 of HIV-1 and boosted with a recombinant gp160. J Infect Dis 1996;174:734-8.